ストックスクリーナーアプリを入手
5.54
3.55%
0.19
プレマーケット:
5.46
-0.08
-1.44%
前日終値:
$5.35
開ける：
$5.35
24時間の取引高:
919.68K
Relative Volume:
0.72
時価総額：
$473.78M
収益：
-
当期純損益:
$-69.31M
株価収益率:
-4.3622
EPS:
-1.27
ネットキャッシュフロー:
$-62.80M
1週間 パフォーマンス:
+5.52%
1か月 パフォーマンス:
+34.14%
6か月 パフォーマンス:
+13.76%
1年 パフォーマンス:
+19.40%
1日の値動き範囲:
$5.325
$5.62
1週間の範囲:
$5.07
$5.62
52週間の値動き範囲:
$2.215
$6.1856
Rezolute Inc Stock (RZLT) Company Profile
名前
Rezolute Inc
セクター
電話
650-206-4507
住所
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
RZLT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
5.54 | 455.78M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-08-27 | 開始されました | Guggenheim | Buy |
| 2024-07-17 | 開始されました | BTIG Research | Buy |
| 2024-06-04 | 開始されました | Craig Hallum | Buy |
| 2024-04-09 | 開始されました | Maxim Group | Buy |
| 2022-08-02 | 再開されました | Canaccord Genuity | Buy |
| 2022-06-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-09-08 | 開始されました | ROTH Capital | Buy |
| 2021-05-27 | 開始されました | Oppenheimer | Outperform |
| 2021-05-25 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Rezolute Inc (RZLT) 最新ニュース
Rezolute posts patient demographics poster for Phase 3 sunRIZE study - Investing.com Australia
Rezolute Completes Enrollment for Phase 3 sunRIZE Study - TipRanks
What drives Rezolute Inc. stock priceUnprecedented profit potential - Jammu Links News
Why Rezolute Inc. stock attracts strong analyst attentionInstant Stock Updates - Newser
What makes Rezolute Inc. stock price move sharplyFree Best Performing Stock Alerts - Newser
How Rezolute Inc. stock performs during market volatilityFree Trading Strategy Suggestions - Newser
Rezolute Announces Presentation of Participant Baseline Data From Its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) - 富途牛牛
Rezolute, Inc. Announces Late-Breaking Presentation of Phase 3 Study Data for Ersodetug at ENDO 2025 - Quiver Quantitative
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) - TradingView
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of “Buy” from Analysts - Defense World
Institutional investors must be pleased after a 11% gain last week that adds to Rezolute, Inc.'s (NASDAQ:RZLT) one-year returns - simplywall.st
Rezolute Inc: chief medical officer Roberts buys $10939 in shares - Investing.com
Rezolute CFO Evans buys $20,250 in company stock - Investing.com
Rezolute director Kim buys shares worth $3.99 million - Investing.com Australia
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Rezolute’s SWOT analysis: ersodetug trials boost stock amid clinical milestones - Investing.com India
Bank of America Corp DE Has $443,000 Stock Position in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Two Sigma Investments LP Sells 12,118 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Squarepoint Ops LLC Sells 3,980 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Millennium Management LLC Decreases Stake in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
69,724 Shares in Rezolute, Inc. (NASDAQ:RZLT) Bought by Ameriprise Financial Inc. - Defense World
Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77% - Yahoo Finance
BTIG maintains $15 target on Rezolute stock following trial update - Investing.com Australia
BTIG maintains $15 target on Rezolute stock following trial update By Investing.com - Investing.com India
Rezolute Announces Completion Of Enrollment In The Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism - marketscreener.com
Rezolute complete enrollment in Phase 3 sunRIZE study of ersodetug - TipRanks
Rezolute (RZLT) Completes Enrollment for Pivotal sunRIZE Study | - GuruFocus
Rezolute (RZLT) Completes Enrollment for Pivotal sunRIZE Study | RZLT Stock News - GuruFocus
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism - The Manila Times
Man Group plc Makes New $425,000 Investment in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update - The Globe and Mail
Rezolute, Inc. (RZLT): A Biotech Breakthrough Poised for Explosive Growth - AInvest
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential - MSN
Rezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Rezolute Inc (NASDAQ: RZLT) Is The Hottest Stock Right Now. - Stocksregister
Balyasny Asset Management L.P. Purchases New Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
HC Wainwright Analysts Lift Earnings Estimates for Rezolute - Defense World
Wedbush Forecasts Rezolute’s FY2025 Earnings (NASDAQ:RZLT) - Defense World
Rezolute (NASDAQ:RZLT) Earns Outperform Rating from Wedbush - Defense World
Rezolute (RZLT) Advances Studies on Hyperinsulinism Treatments | - GuruFocus
Rezolute (RZLT) to Release Earnings on Wednesday - Defense World
Rezolute Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rezolute (RZLT) Advances Studies on Hyperinsulinism Treatments | RZLT Stock News - GuruFocus
Rezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia Treatment - Nasdaq
Rezolute Secures FDA Breakthrough Status as Phase 3 Trial Nears Full Enrollment - Stock Titan
Barclays PLC Takes Position in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Hypoglycemia Market Poised for Notable Growth by 2032, Fueled - openPR.com
Rezolute Inc (RZLT) 財務データ
収益
当期純利益
現金流量
EPS
Rezolute Inc (RZLT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Evans Daron | CFO |
Jun 24 '25 |
Buy |
4.05 |
5,000 |
20,250 |
268,900 |
| Kim Young-Jin | Director |
Jun 13 '25 |
Buy |
3.25 |
1,230,769 |
3,999,999 |
8,423,386 |
| KREHER NERISSA | Director |
Jun 13 '25 |
Buy |
3.25 |
3,076 |
9,997 |
37,576 |
| Hogenhuis Wladimir | Director |
Mar 31 '25 |
Buy |
2.92 |
6,758 |
19,733 |
84,025 |
| Elam Nevan C | CEO |
Mar 27 '25 |
Buy |
2.85 |
12,302 |
34,999 |
224,119 |
| Evans Daron | CFO |
Mar 26 '25 |
Buy |
2.89 |
10,000 |
28,900 |
237,900 |
| Evans Daron | CFO |
Mar 26 '25 |
Buy |
2.88 |
10,000 |
28,800 |
23,000 |
| Hogenhuis Wladimir | Director |
Feb 18 '25 |
Buy |
4.70 |
10,000 |
47,000 |
77,267 |
| Evans Daron | CFO |
Dec 18 '24 |
Buy |
4.29 |
10,000 |
42,900 |
150,900 |
| Evans Daron | CFO |
Dec 12 '24 |
Buy |
4.60 |
9,000 |
41,400 |
140,900 |
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):